Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Alsaadi et al. [4] 2008 RS 6/28 RA NR 24 100% (6/6)
100% (28/28)c 		NR NR NR NR
Mozzati et al. [5] 2021 RS 19/40 RA 1/18 Mean: 63.4 84.2% (16/19)
90% (36/40)
Early loss: 4
Late loss: 0 		NR Mean: 0.42 NR NR
Petsinis et al. [7] 2017 RS 11/37 RAb 2/9 Mean: 59.8 90.9% (10/11)
97.3% (36/37)
Early loss: 0
Late loss: 1 		NR NR 9.1% (1/11)
2.7% (1/37) 		NR
Bertl et al. [24] 2019 RS 21/NR RA NR Up to prosthetic loading 100% (21/21)
NRd 		NR NR NR NR
Binon [34] 2005 CR 1/6 RA+sSS 1/0 156 100% (1/1)
100% (6/6) 		100% (1/1)
100% (1/1) 		NR NR NR
Gaur et al. [43] 2021 CR 1/18 RA 0/1 48 0% (0/1)
94.4% (17/18)
Early loss: 0
Late loss: 1 		100% (2/2)
100% (2/2) 		NR 0% (0/1)
0% (0/18) 		NR
Peron et al. [58] 2017 CR 1/5 RA+sSS 0/1 36 100% (1/1)
100% (5/5) 		NR 0 NR NR
de Mendonça Invernici et al. [66] 2014 CR 1/2 RA+sSS 0/1 72 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		0 NR NR
Alsaadi et al. [67] 2008 RS NR/14 RA NR Up to prosthetic loading NR
92.9% (13/14)d 		NR NR NR NR
Krennmair et al. [71] 2010 RS 25/85 RA 0/25 Mean: 46.6 100% (25/25)
100% (85/85) 		100% (25/25)
100% (33/33) 		Median: 2 NR NR
96.5% (82/85)e,f
9/41 RA+sSS, RA+sSS+SSc, RA+DM 0/9 Mean: 48.9 100% (9/9)
100% (41/41) 		100% (9/9)
100% (10/10) 		Median: 2.8 NR NR
90.2% (37/41)e,f
Payne et al. [81] 1997 CS 1/12 RA+sSS 0/1 96 0% (0/1)
75% (9/12)
Early loss: 2,
Late loss: 1 		100% (1/1)
100% (2/2) 		NR NR NR
Alenazi [84] 2021 CCS 14/32 RA 5/9 Mean: 42.3 100% (14/14)
100% (32/32) 		100% (14/14)
NR 		Median: 1.2 NR NR
14/43 RA+SSc, RA+sSS
RA+DM 		4/10 Mean: 44.6 100% (14/14)
100% (43/43) 		100% (14/14)
NR 		Median: 2.2 NR NR
14/39 Control group 7/7 Mean: 39.4 100% (14/14)
100% (39/39) 		100% (14/14)
NR 		Median: 0.6 NR NR
Overall
RA - RS: 6
CR: 4
CS: 1
CCS: 1 		124/363 - Ratio: 1/6.5 Mean: 50.8 95.2% (118/124)
97.2% (353/363)
Of these: 70% (7/10) early loss 		100% (67/67)
100% (49/49) 		Mean: 0.36
Median: 2 		8.3% (1/12)
1.8% (1/55) 		NR
94.4% (119/126)e,f
RA
+ concomitant ADs 		- CR: 3
CS: 1
CCS: 1
RS: 1 		27/109 - Ratio: 1/4.4 Mean: 52.8 96.3% (26/27)
97.2% (106/109)
Of these: 66.7% (2/3) early loss 		100% (26/26)
100% (14/14) 		Mean: 0
Median: 2.2 		NR NR
90.2% (37/41)e,f
Control group - CCS: 1 14/39 - Ratio: 1/1 Mean: 39.4 100% (14/14)
100% (39/39) 		100% (14/14)
NR 		Median: 0.6 NR NR

a = weighted mean or median; b = remission at implant placement; c = early loss NR; d = late loss NR; e = criteria by Buser et al. [116]; f = criteria by Karoussis et al. [117].
ADs = autoimmune diseases; CCS = case-control study; CR = case report; CS = case series; DM = dermatomyositis; M/F = male/female; N = number; NR = not reported; PI = peri-implantitis; RS = retrospective study; SSc = systemic scleroderma; sSS = secondary Sjögren's syndrome.